Brimarafenib is an investigational new drug that is being evaluated for the treatment of cancer. It targets the proto-oncogene BRAF with activating mutations BRAF mutations (such as V600E), non-V600 BRAF mutations, and RAF fusions.
It is being developed by MapKure, LLC, a joint venture between SpringWorks Therapeutics and BeiGene.
References